 |
|
|
 |
"Operation Cure-All" Wages New Battle In Ongoing War Against Internet Health Fraud
As part of an ongoing and comprehensive law enforcement and consumer education campaign begun in 1997, the Federal Trade Commission today announced a new round of enforcement actions against the fraudulent marketing of supplements and other health products on the Internet. The FTC's action is part of a coordinated effort with the U.S. Food and Drug Administration (FDA), Health Canada, and various state Attorneys General to crack down on unscrupulous marketers who use the Internet to prey on the sickest and most vulnerable consumers. The six new FTC enforcement actions target companies marketing a variety of devices, herbal products, and other dietary supplements to treat or cure cancer, HIV/AIDS, arthritis, hepatitis, Alzheimer's, diabetes and many other diseases. Among the many products for which unfounded claims were being made were a DHEA hormonal supplement, St. John's Wort, various multi-herbal supplements, colloidal silver and a variety of electrical therapy devices. The FTC's cases were also prompted by representations by some marketers that their products are safe when, in fact, there may be potentially dangerous interactions with other medications. more
|
|
Investigation Of Human Health Effects Associated With Potential Exposure To Genetically Modified Corn
In response to a request from EPA in October of 2000 the US Food and Drug Administration (FDA) requested assistance from the Centers for Disease Control and Prevention (CDC) in investigating possible adverse health effects among people who had reported to FDA that they may have had an allergic reaction to eating corn products contaminated with the Cry9c protein in StarLink™ corn. The CDC’s investigation did not find any evidence that hypersensitivity to the Cry9c protein was responsible for the self-reported allergic responses that people experienced last fall, but did comment on the difficulty of investigating a genetic agent that appears in the food supply without approval. Get the complete report in today's issue of Vidyya. more
|
|
|
|
Trends in Pregnancy Rates For The United States, 1976-97: An Update
In 1997 an estimated 6.19 million pregnancies resulted in 3.88 million live births, 1.33 million induced abortions, and 0.98 million fetal losses. The 1997 pregnancy rate of 103.7 pregnancies per 1,000 women aged 15–44 years is the lowest recorded since 1976 (102.7), the first year for which a consistent series of national pregnancy rates is available. The 1997 rate was 10 percent lower than the peak rate in 1990 (115.6). The teenage pregnancy rate dropped steadily through 1997, falling to a record low of 94.3 pregnancies per 1,000 teenagers 15–19 years, 19 percent below the 1990 level (116.3). Rates for younger teenagers declined more than for older teenagers. This report presents detailed pregnancy rates for 1996 and 1997 to update a recently published comprehensive report on pregnancies and pregnancy rates for US women. more
|
|
Recurrence Of Head And Neck Cancer Slowed By Novel New Therapy
Promising results from a study led by University of Pittsburgh Cancer Institute (UPCI) researcher, Dong Moon Shin, MD, suggest that treating head and neck cancer patients with a combination of the biologic agents retinoid, interferon, and vitamin E may lead to improved survival for patients with a locally advanced stage of the disease and result in few negative side-effects. Results from the study are published in the 15 June 2001 issue of the Journal of Clinical Oncology. more
|
|
Migraine Medication, Relpax (Eletriptan Hydrobromide) Receives EU Approval
Relpax (eletriptan hydrobromide), an anti-migraine medicine for the acute treatment of migraine in adults, has completed the European Mutual Recognition process. In addition to mutual recognition by EU member countries, Non-EU members such as Norway have agreed as well to recognize the earlier approval of relpax by the reference member state, the United Kingdom. more
|
|
|
